Hypothesis

Serial passaging of bone‑marrow MSCs leads to a progressive, quantifiable loss of positional HOX expression through increased H3K27me3 deposition at 5′ HOX clusters, a process driven by oxidative‑stress‑mediated activation of EZH2. This epigenetic drift predicts declining osteogenic and adipogenic differentiation capacity, and it's rescuable by EZH2 inhibition or NAD+ replenishment.

Mechanistic Rationale

• It's driven by oxidative stress from mitochondrial dysfunction, which elevates ROS that inhibit SIRT1 deacetylase activity.
• Reduced SIRT1 leads to hyperacetylation and stabilization of EZH2, and it's this stabilization that enhances PRC2 catalytic activity.
• EZH2 deposits H3K27me3 at CpG‑rich promoters of anterior HOX genes (e.g., HOXA5, HOXC9), silencing their transcription.
• Loss of HOX transcription attenuates downstream Wnt/β‑catenin signaling, impairing lineage‑specific transcription factors such as RUNX2 and PPARγ.

Testable Predictions

1. Correlation – We're expecting passage number (P5‑P30) to show a linear increase in H3K27me3 signal at HOXA5 and HOXC9 promoters (ChIP‑qPCR) and a reciprocal decrease in mRNA (RT‑qPCR) across BM‑MSCs from three donors.
2. Functional link – MSCs with >2‑fold H3K27me3 gain will exhibit ≥40 % reduction in Alizarin Red staining (osteogenesis) and Oil‑Red O accumulation (adipogenesis) compared with low‑passage controls.
3. Rescue – Treatment with EZH2 inhibitor GSK126 (1 µM) or NAD+ booster NR (1 mM) during passages 15‑20 will restore HOX expression to ≥80 % of early‑passage levels and rescue differentiation efficiency.
4. Specificity – Posterior HOX genes (HOXD13) will show minimal change, reflecting the known 5′‑to‑3′ gradient of PRC2 sensitivity.

Experimental Outline

• Isolate BM‑MSCs from donors aged 20‑40 y, expand to P5, P10, P15, P20, P25, P30.
• Measure ROS (DCFDA), SIRT1 Western blot, EZH2 activity (H3K27me3 ELISA).
• Perform ChIP‑qPCR for H3K27me3 at HOXA5, HOXC9, HOXD10 promoters.
• Quantify HOX transcripts (RT‑qPCR) and differentiation assays.
• Apply interventions in parallel cultures; repeat assays.

Potential Confounders & Controls

• Use fibroblast cultures as negative control (they already show HOXC10 loss per 1).
• Include antioxidant NAC to dissect ROS‑specific effects.
• Verify that GSK126 does not affect cell viability at used concentrations (MTT assay).

Falsifiability

If passage‑dependent H3K27me3 increase does not correlate with HOX silencing, or if EZH2/NAD+ manipulation fails to restore HOX expression and differentiation, the hypothesis is refuted.

Significance

Demonstrating a mechanistic link between culture‑induced oxidative stress, PRC2 activity, and positional identity loss would provide a concrete biomarker for MSC manufacturing quality and suggest epigenetic rejuvenation strategies to preserve therapeutic potency.